Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Vaccinia virus (VACV) confers cross-protective immunity against the variola virus, the causative agent of smallpox, and has therefore been extensively exploited as a preventive vaccine.

One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% ...

The immune system can typically ramp up the body's defenses to clear out an invading threat without issue. Glitches can ...

Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

One of the molecular fragments (pink) uncovered using fragment-based drug discovery is shown binding with an immune system enzyme called Vaccinia-H1-related phosphatase.

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have received an average recommendation of “Buy” from the seven ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...